Category: ARV
New Study: The Impact of the COVID-19 Health Crisis on Access to HIV Services in Egypt, Morocco, Mauritania, and Tunisia.
A study was carried out by the FORSS consortium which includes (ITPC-MENA, Solidarité SIDA, AGD, ATP+, Al Shehab RdR Maroc, and M-Coalition). This recently developed report analyzes the impact of the COVID-19 pandemic on HIV-related health services in the MENA...
The MENA Community Advisory Board (MENA-CAB) 2017 Report
The Community Advisory Board (CAB) constitutes a space of exchange between advocates from the MENA region, researchers and drug manufacturers, with the aim to educate people living with HIV and their advocates on access to treatment, to disseminate information about...
Civil Society Speaks: Fighting for Universal Access To Dolutegravir (DTG)!
Source : The Global Network of People living with HIV GNP+ What do people living with HIV need to know about Dolutegravir? What do our communities need to know about viral resistance to first line ARVs? GNP+ invites you to...
IAS 2017: Closing ceremony exposes Gilead Sciences
Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” Yesterday, the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), drew to a close, in style. The community address delivered by Othoman Mellouk, during the closing...
A new victory for ITPC-MENA : Bristol-Myers Squibb extends its voluntary license on Atazanavir to Egypt
The 9th International AIDS Society Conference on HIV / AIDS 2017 : Bristol-Myers Squibb extends its voluntary license on Atazanavir to Egypt, a victory for ITPC-MENA Today, at the World Conference on AIDS, which is currently taking place in Paris...
BLOG: We want dolutegravir for all, and we want it now
Source: makemedicinesaffordable Author: Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC). Article first published on the Huffington Post here. We’re calling for a compulsory license on a ‘new’ HIV drug to be...
HIV Activists Denounce ViiV for Denying 3.5 million People Access to Optimal Treatment
Source : ITPC GLOBAL Today, Monday, 24 July 2017, during the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), HIV treatment activists from around the world collectively blocked access to ViiV Healthcare’s promotional booth and stormed its...
ITPC MENA IN THE REGIONAL CONSULTATION ON ACCELERATING ACCESS TO THE CONTIUUM OF HIV CARE: FOCUS ON HIV TESTING
Beirut, Lebanon, 12–14 July 2017 By the end of 2015, the estimated number of people living with HIV in the Region had reached 330 000. With a continuously growing epidemic coupled with low coverage of ART, standing at 14% of...
New WHO Guidance Report- Treatment Failure and Drug Resistance
WHO urges action against HIV drug resistance threat 20 JULY 2017 | GENEVA - WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted in several countries. The Organization warns...
US Supreme Court Adopts International Exhaustion For Patents: Paving the way for parallel imports to exert downward pressure on domestic pharmaceutical (and other) prices
Source : By Frederick M The Supreme Court of the United States on May 30, 2017 adopted a rule of international exhaustion of patent rights for the United States in Impression Products v. Lexmark International, No. 15-1189. The near-unanimous decision...